阿托伐他汀对慢性心功能不全合并阵发性房颤预后的影响

Effects of atorvastatin on inflammatory level and clinical prognosis in patients with chronic congestive heart failure and paroxysmal atrial fibrillation

目的:探讨阿托伐他汀对慢性心功能不全合并阵发性房颤患者炎症水平以及临床预后的影响。方法:入选慢性心功能不全合并阵发性心房颤动患者135例,分为阿托伐他汀组(72例)和对照组(63例);随访18个月,测定两组患者治疗前、后第1、6、18个月C反应蛋白(CRP)水平;比较两组患者治疗前后的血脂水平、左房内径、左室射血分数;随访阵发性房颤的再发率,转化为持续性和永久性房颤的发生率和心脑血管事件(心衰恶化、心源性死亡、缺血性脑卒中)。结果:与对照组比较,阿托伐他汀治疗后CRP水平明显降低,随访期内阵发性房颤再发率、转化为持续性、永久性房颤的概率明显减少,且治疗组的心脑血管事件发生率较低。结论:阿托伐他汀能降低慢性心力衰竭合并阵发性心房颤动患者的CRP水平,减少阵发性房颤复发、进展,同时减少心脑血管事件的发生。

Objective：To investigate the effects of atorvastatin on inflammatory level and clinical prognosis in patients with chronic congestive heart failure and paroxysmal atrial fibrillation （AF）. Methods：A total of 135 patients with chronic congestive heart failure and paroxysmal AF were divided into atorvastatin group （72 eases） and control group （63 cases）. During the 18 months＇ follow-up, CRP and serum lipid level, left atrial diameter and left ventricular function were measured. In addition, we also evaluated the recurrence of paroxysmal AF and the incidences of persistent and permanent AF, and cardiocerebral vascular events. Results：After atorvastatin treatment, the levels of CRP at 1-month, 6- month, 18-month were diminished significantly. Lipid levels were also improved markedly in atorvastatin group. During 18-month following-up, the recurrence of paroxysmal AF and incidence of persistent and permanent AF, and cardiocerebral vascular events were decreased in atorvastatin group. Conclusion： Atorvastatin could reduce the CRP level and decrease the recurrence of paroxysmal AF, and incidences of persistent and permanent AF, which also attenuated the cardiocerebral vascular events in follow=up.